Biotechnology has all the time been a dynamic area, however the world of finance that gives the gasoline for the fireplace is simply as vibrant. Attempting to foretell the place the marketplace for biotech funding is heading is all the time dangerous however for consultants like Baker McKenzie’s Roel Meers, understanding the place the market is shifting is the place he eats.
I spoke to Roel this week to unpack simply the place biotech funding stands in Q2 2025, to get a really feel for the types of M&As, IPOs, and licensing offers we needs to be on the lookout for within the second half of the yr. We additionally discuss some different financing choices for innovators and early-stage companies.
01:09 Introducing Roel Meers
02:18 Company finance and the life sciences
04:53 Brussels, Europe, and past: Baker McKenzie’s world footprint
06:21 Navigating life science rules and regulators
10:33 De-risking biotech investments in unsure instances
11:57 How traders are minimizing threat in 2025
13:35 Funding developments for biotechs in rising hubs, together with Benelux
15:58 The deal sorts that can dominate 2025
17:35 The therapeutic areas the place offers are being completed
19:16 Tendencies in biotech in Europe, in North America, and within the Asia-Pacific
20:36 Macroeconomics and biotechnology finance
22:54 De-risking offers by reducing upfronts, growing milestones
26:38 What to think about when selecting different financing choices
30:35 When ought to biotechs usher in outdoors finance consultants
33:47 Wanting past 2025 – what’s coming, and why
36:38 How European biotechs can place themselves for funding success
Considering being a sponsor of an episode of our podcast? Uncover how one can get entangled right here!
Keep up to date by subscribing to our publication
To dive deeper into the subject:
Company finance and the life sciences
Brussels, Europe, and past: Baker Mackenzie’s world footprint
Navigating life science rules and regulators
De-risking biotech investments in unsure instances
How traders are minimizing threat in 2025
Funding developments for biotechs in rising hubs, together with Benelux
The deal sorts that can dominate 2025
The therapeutic areas the place offers are being completed
Tendencies in biotech in Europe, in North America, and within the Asia-Pacific
Macroeconomics and biotechnology finance
De-risking offers by reducing upfronts, growing milestones
What to think about when selecting different financing choices
When ought to biotechs usher in outdoors finance consultants
Wanting past 2025 – what’s coming, and why
How European biotechs can place themselves for funding success
